The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in ...
The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the ...
Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings ...
France’s government faces its highest borrowing costs this year after Emmanuel Macron’s shock decision to call a ...
Happy Monday! One of your Morning Dispatchers has received some flak during recent Dispatch editorial meetings for wearing ...
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug ...
The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. Engadget ...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer ...
US FDA approves GSK’s respiratory syncytial virus vaccine, Arexvy for adults aged 50-59 at increased risk: London, UK Monday, June 10, 2024, 10:00 Hrs [IST] GSK plc announced th ...